137 related articles for article (PubMed ID: 35410781)
1. Status of IDH mutations in chondrosarcoma of the jaws.
You Z; Zhang J; Zhang H; Li X; Sun Z; Sun L
Int J Oral Maxillofac Surg; 2023 Jan; 52(1):26-31. PubMed ID: 35410781
[TBL] [Abstract][Full Text] [Related]
2. IDH mutation status in a series of 88 head and neck chondrosarcomas: different profile between tumors of the skull base and tumors involving the facial skeleton and the laryngotracheal tract.
Tallegas M; Miquelestorena-Standley É; Labit-Bouvier C; Badoual C; Francois A; Gomez-Brouchet A; Aubert S; Collin C; Tallet A; de Pinieux G
Hum Pathol; 2019 Feb; 84():183-191. PubMed ID: 30296521
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of IDH mutations in chondrosarcoma.
Nakagawa M; Sekimizu M; Endo M; Kobayashi E; Iwata S; Fukushima S; Yoshida A; Kitabayashi I; Ichikawa H; Kawai A; Nakatani F
J Orthop Sci; 2022 Nov; 27(6):1315-1322. PubMed ID: 34531086
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
[TBL] [Abstract][Full Text] [Related]
5. Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.
Denu RA; Yang RK; Lazar AJ; Patel SS; Lewis VO; Roszik J; Livingston JA; Wang WL; Shaw KR; Ratan R; Zarzour MA; Bird J; Raza S; Akdemir KC; Rodon Ahnert J; Subbiah V; Patel S; Conley AP
Clin Cancer Res; 2023 Dec; 29(23):4844-4852. PubMed ID: 37747813
[TBL] [Abstract][Full Text] [Related]
6. Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta-analysis.
Vuong HG; Ngo TNM; Dunn IF
Cancer Med; 2021 Jul; 10(13):4415-4423. PubMed ID: 34085407
[TBL] [Abstract][Full Text] [Related]
7. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC
Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
Chen S; Fritchie K; Wei S; Ali N; Curless K; Shen T; Brini AT; Latif F; Sumathi V; Siegal GP; Cheng L
Hum Pathol; 2017 Jul; 65():239-246. PubMed ID: 28552826
[TBL] [Abstract][Full Text] [Related]
9. Genomic Profiling Identifies Association of
Zhu GG; Nafa K; Agaram N; Zehir A; Benayed R; Sadowska J; Borsu L; Kelly C; Tap WD; Fabbri N; Athanasian E; Boland PJ; Healey JH; Berger MF; Ladanyi M; Hameed M
Clin Cancer Res; 2020 Jan; 26(2):419-427. PubMed ID: 31615936
[TBL] [Abstract][Full Text] [Related]
10. IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience.
Setola E; Benini S; Righi A; Gamberi G; Carretta E; Ferrari C; Avnet S; Palmerini E; Magagnoli G; Gambarotti M; Lollini PL; Cesari M; Cocchi S; Paioli A; Longhi A; Scotlandi K; Laginestra MA; Donati DM; Baldini N; Ibrahim T
BMC Cancer; 2023 Sep; 23(1):907. PubMed ID: 37752419
[TBL] [Abstract][Full Text] [Related]
11. Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis.
Lam SW; van Langevelde K; Suurmeijer AJH; Cleven AHG; Bovée JVMG
Histopathology; 2019 Dec; 75(6):843-852. PubMed ID: 31297850
[TBL] [Abstract][Full Text] [Related]
12. Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation.
Pathmanapan S; Poon R; De Renshaw TB; Nadesan P; Nakagawa M; Seesankar GA; Ho Loe AK; Zhang HH; Guinovart JJ; Duran J; Newgard CB; Wunder JS; Alman BA
Cell Rep; 2023 Jun; 42(6):112578. PubMed ID: 37267108
[TBL] [Abstract][Full Text] [Related]
13. Conventional chondrosarcoma of the rib cage and sternum: clinicopathological and molecular analysis of 27 patients treated at a single institution.
Abdulfatah E; Rottmann D; Morag Y; Pantanowitz L; Udager AM; Hao W; Lucas DR
Hum Pathol; 2023 Jun; 136():63-74. PubMed ID: 37019410
[TBL] [Abstract][Full Text] [Related]
14. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.
Amary MF; Bacsi K; Maggiani F; Damato S; Halai D; Berisha F; Pollock R; O'Donnell P; Grigoriadis A; Diss T; Eskandarpour M; Presneau N; Hogendoorn PC; Futreal A; Tirabosco R; Flanagan AM
J Pathol; 2011 Jul; 224(3):334-43. PubMed ID: 21598255
[TBL] [Abstract][Full Text] [Related]
15. IDH1 Mutation Induces HIF-1
Hu X; Li L; Eid JE; Liu C; Yu J; Yue J; Trent JC
Dis Markers; 2022; 2022():7729968. PubMed ID: 35198082
[TBL] [Abstract][Full Text] [Related]
16. Association of Clinicopathological Features With Outcome in Chondrosarcomas of the Head and Neck.
Asioli S; Ruengwanichayakun P; Zoli M; Guaraldi F; Sollini G; Greco P; Facco C; Gibertoni D; Jiménez BV; Benini S; Turri-Zanoni M; Pasquini E; Mazzatenta D; Foschini MP; Righi A
Otolaryngol Head Neck Surg; 2021 Apr; 164(4):807-814. PubMed ID: 32928034
[TBL] [Abstract][Full Text] [Related]
17. IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas.
Damato S; Alorjani M; Bonar F; McCarthy SW; Cannon SR; O'Donnell P; Tirabosco R; Amary MF; Flanagan AM
Histopathology; 2012 Jan; 60(2):363-5. PubMed ID: 22074484
[No Abstract] [Full Text] [Related]
18. A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma.
Rey V; Tornín J; Alba-Linares JJ; Robledo C; Murillo D; Rodríguez A; Gallego B; Huergo C; Viera C; Braña A; Astudillo A; Heymann D; Szuhai K; Bovée JVMG; Fernández AF; Fraga MF; Alonso J; Rodríguez R
EBioMedicine; 2024 Apr; 102():105090. PubMed ID: 38547578
[TBL] [Abstract][Full Text] [Related]
19. Synovial chondrosarcoma: a single-institution experience with molecular investigations and review of the literature.
Gambarotti M; Pacheco M; Ruengwanichayakun P; Silvino Vega Jiménez B; Benini S; Bianchi G; Sbaraglia M; Vanel D; Carretta E; Bertoni F; Franchi A; Dei Tos AP; Righi A
Histopathology; 2020 Sep; 77(3):391-401. PubMed ID: 32506447
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.
Nakagawa M; Nakatani F; Matsunaga H; Seki T; Endo M; Ogawara Y; Machida Y; Katsumoto T; Yamagata K; Hattori A; Fujita S; Aikawa Y; Ishikawa T; Soga T; Kawai A; Chuman H; Yokoyama N; Fukushima S; Yahiro K; Kimura A; Shimada E; Hirose T; Fujiwara T; Setsu N; Matsumoto Y; Iwamoto Y; Nakashima Y; Kitabayashi I
Oncogene; 2019 Oct; 38(42):6835-6849. PubMed ID: 31406254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]